Target intelligence / Profile preview

MicroRNA 208b (miR-208b)

Target
miR-208b
Molecular classification
MicroRNA, Non-coding RNA, MyomiR (muscle-specific microRNA family)
01

Overview

MicroRNA 208b is a highly conserved, muscle-specific non-coding RNA molecule encoded by an intron of the Myh7 gene. It is expressed primarily in cardiac and skeletal muscle tissue, where it regulates muscle fiber type specification and gene expression by targeting mRNAs through binding to their 3′ untranslated regions, leading to inhibition of protein translation. miR-208b functions in a network with other myomiRs and targets (e.g., Mettl8), playing an important role in the transition from fast-twitch to slow-twitch muscle fibers and influencing normal muscle development as well as disease states, such as cardiac remodeling and skeletal muscle pathology[1][4]. It is increasingly recognized as a valuable biomarker for myocardial injury, and experimental therapeutics are focused on modulating its activity for potential disease intervention.

Other names
miR-208bMIR208Bhsa-mir-208bMIRN208B
02

Mechanism of action

Antagomirs or inhibitors: Bind and inhibit miR-208b function, derepressing its target mRNAs - Mimics: Supplement endogenous miR-208b, enhancing its regulatory effect

03

Biological functions

Post-transcriptional regulation of gene expressionRegulation of muscle fiber type conversion (promotes transition from fast-twitch to slow-twitch fibers by inhibiting Mettl8)Modulation of cardiac and skeletal muscle development and adaptationRegulation of myosin heavy chain expression and related contractile proteinsInhibition of target gene protein translation through 3′UTR binding
04

Disease associations

Cardiovascular disease, especially heart failure and cardiac remodelingSkeletal muscle disease and muscle fiber specificationPotential roles in other disorders involving muscle metabolism or differentiation (ongoing research)
05

Safety considerations

Targeting miR-208b may risk unintended systemic effects, as it plays crucial roles in heart and skeletal muscle homeostasisModulating miR-208b could alter muscle fiber composition or cardiac contractility, requiring careful therapeutic control
06

Interacting drugs

There are currently no approved drugs that directly target miR-208b, but research is ongoing into miRNA-based therapeutics and diagnostic applications.

1 more in the full profile.

07

Biomarkers

Circulating miR-208b is proposed as a biomarker for myocardial injury and diagnosis of acute myocardial infarction and heart failureDiagnostic value is being explored in several cardiovascular disorders

Beyond the preview

Go deeper on MicroRNA 208b (miR-208b).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 208b (miR-208b).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call